Leng et al. 52 week results tocilizumab biosimilar vs originator in RA. Shocker, it's the same. @RheumNow #ACR22 Abstr#0917
Fifty-two-week Results from a Phase 3, Randomized, Double-blind, Active-controlled Clinical Trial to Compare BAT1806/BIIB800, a Proposed Tocilizumab Biosimilar, with a Tocilizumab Reference Product in Subjects with Moderate to Severe RA with an Inadequate Response to Methotrexate - ACR Meeting Abstracts
